Altamira Therapeutics Ltd - Company Profile
Powered by 
All the data and insights you need on Altamira Therapeutics Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Altamira Therapeutics Ltd Strategy Report
- Understand Altamira Therapeutics Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Altamira Therapeutics Ltd (Altamira Therapeutics) is a biopharmaceutical company that develops therapies for unmet medical needs in neurotology and central nervous system disorders. The company operates through one reportable segment, which includes the development of pharmaceutical products for the treatment and prevention of peripheral and central nervous disorders.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company undertakes research to advance its pipeline candidates for the treatment of acute inner ear tinnitus, sudden loss of hearing, post-acute inner ear tinnitus, tinnitus, antipsychotic-induced weight gain, and vertigo. It is developing two pipline products AM-401 for the treatment of KRAS driven cancer and AM-411 for rheumatoid arthritis. Altamira Therapeutics' R&D activities also include costs incurred for the production of the pre-clinical compounds and costs paid to academic research institutions for pre-clinical testing. In FY2022, the company spent CHF7.2 million on R&D activities.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer